Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial.
Salvati. F F; Rasi. G G; Portalone. L L; Antilli. A A; Garaci. E E
Key Findings
- Time to progression was significantly longer with the chemo‑immunotherapy combo (p=0.0059).
- Immune cell counts (CD4+, CD8+, NK) stayed stable in the combo group, unlike the drop seen after chemo alone.
- Grade 3/4 hematologic toxicity occurred in 50% of chemo‑only patients but none in the combo group.
Practical Outcomes
- For cancer patients, adding thymosin‑alpha1 plus low‑dose IFN‑alpha may be a low‑risk way to improve outcomes and reduce toxicity, but the evidence is limited and not yet ready for general use. It’s not a protocol for healthy individuals seeking longevity or performance gains.
Summary
A small study in advanced lung cancer patients found that adding thymosin‑alpha1 and low‑dose interferon‑alpha after chemotherapy didn’t dramatically boost tumor shrinkage, but it did slow disease progression, kept immune cells from dropping, and cut serious blood‑related side effects compared to chemo alone.
Abstract
22 patients with advanced non-small-cell lung cancer were randomized to receive chemotherapy (ifosfamide) or chemotherapy followed by thymosin alpha1 + low-dose IFNalpha. Chemo-immunotherapy induced an enhanced response rate compared with chemotherapy alone (33% and 10% respectively). Although these differences were not significant, the difference in time to progression was (p=0.0059). CD4+, CD8+ and NK cell counts were significantly depressed after two cycles of chemotherapy, while no difference in cell count were seen in chemo-immunotherapy treated patients. Hematologic toxicity was reduced by the immunotherapy, with no grade 3/4 toxicity seen compared to 50% in patients treated with chemotherapy alone.
Study Information
pubmed
1996